Phase III Trial Comparing Standard Maintenance Therapy Alone or With Local Consolidative Radiation in Adults with 1-5 Sites of Oligometastatic Non-Small Cell Lung Cancer
Led by Tata Memorial Hospital · Updated on 2025-09-10
190
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare two treatment approaches for adults with oligometastatic non-small cell lung cancer NSCLC, where cancer has spread to 1 to 5 sites. It evaluates standard maintenance therapy alone against a combination of local consolidative radiation therapy plus standard maintenance therapy. The study is a Phase III randomized controlled trial sponsored by Tata Memorial Hospital, focusing on improving outcomes for patients with this specific stage of lung cancer.
Participants are assigned randomly to one of two groups one receiving standard maintenance therapy as determined by their oncologist, and the other receiving local consolidative radiation therapy targeting all visible metastatic sites and the primary tumor, alongside standard maintenance therapy. Radiation treatment follows specific dose regimens and targets both the primary and metastatic sites. The study also includes observation periods and monitoring as part of the maintenance therapy.
During the trial, participants will undergo regular assessments including imaging to monitor cancer progression, blood tests to check organ function, and quality of life questionnaires using the EORTC-QLQ-C30 and LC13 tools every three months up to two years. The main outcome measured is overall survival over two years, with secondary outcomes including progression-free survival, local control of treated sites, appearance of new metastases, treatment response rates, and radiation-related side effects. Safety and health status will be closely monitored throughout the study period.
CONDITIONS
Brief Title
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
Research Team
D
Dr. Anil Tibdewal
D
Dr. Jai Prakash Agarwal
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pathologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
1 to 5 metastatic disease sites visible on imaging (no more than 3 lesions in one organ)
Completed 4 to 6 cycles of standard systemic therapy without disease progression
Suitable for definitive treatment to the primary tumor
All metastatic lesions must be visible and suitable for ablative radiation doses
Previous ablative radiation, surgery, or radiofrequency ablation for metastatic sites allowed if total sites are 5 or fewer
Palliative radiation or radiofrequency ablation for symptomatic bone metastases allowed if controlled on imaging
Surgical decompression or stabilization for bone metastases allowed if controlled on imaging and fewer than 5 metastatic sites
Adequate bone marrow function with ANC ≥ 500 cells/mm3, platelets ≥ 50,000 cells/mm3, hemoglobin ≥ 8.0 g/dl
Negative pregnancy test for females of child-bearing potential within 14 days prior to registration
Willingness to provide written informed consent and comply with follow-up schedule
You will not qualify if you...
Progressive disease after initial systemic therapy
Presence of oncogene driver mutations
More than 5 metastatic sites
Metastatic lesions larger than 5 cm
More than 3 metastatic lesions in one organ
Unsuitable for definitive radiation to primary tumor
Unsuitable for ablative radiation to metastatic sites
Malignant peritoneal disease
Malignant pleural effusion
Leptomeningeal disease
Brain metastases located in the brain stem
Spinal cord compression or metastases within 2 mm of spinal cord on MRI
Severe active comorbidities such as unstable angina or congestive heart failure requiring recent hospitalization
Recent transmural myocardial infarction within 6 months
Respiratory illness requiring hospitalization or preventing study therapy
Prior radiation therapy to the chest
History of other malignancies within last 3 years
Pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 years
Participants receive either standard maintenance therapy alone or local consolidative radiation therapy combined with standard maintenance therapy.
Visits every 3 months for assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Feasibility Study of Personalized Atezolizumab Dosing Using Therapeutic Drug Monitoring in Advanced Cancer Patients
Investigating Ubamatamab With and Without Marlotamig in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer
Comparing Single-Session Radiosurgery to Five-Session Stereotactic Radiotherapy With Integrated Boost
for Bone Metastases in Oligometastatic Cancer
Phase 2 Study of Autologous LN-145 Tumor Infiltrating Lymphocyte Therapy for Metastatic Non-Small-Cell Lung Cancer
Chemoimmunotherapy Followed by Surgery and Possible Radiation for Limited Spread Esophageal and Gastric Cancer TORO Protocol
Study on Collecting Blood and Tumor Tissue Samples in Patients with Oncogene-Driven or Early-Stage Non-Small Cell Lung Cancer Undergoing Targeted or Neoadjuvant Immunotherapy
Phase II Study Comparing TKI Alone Versus TKI Plus Local Consolidative Radiation Therapy for Patients With Driver-Mutated Oligometastatic Non-Small Cell Lung Cancer
Phase 3 Study of PD-1 Inhibitor With or Without Local Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma
National Study on Local Ablative Therapy for Patients With Oligometastatic Non-Hematological Cancer
Assessing Surgery, Radiotherapy, Thermal Ablation, and Electroporation Treatments
Phase III Study of SBRT Combined With All-trans Retinoic Acid to Protect Lymphocytes in Adults With Oligo-metastatic Solid Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial.
Anil Tibdewal, Jai Prakash Agarwal, Shashank Srinivasan...